Article by: anees

To clinical trial of vaccine sprayed into the nose Shionogi Pharmaceutical Co., Ltd. from FY2010

　Shionogi Pharmaceutical Co., Ltd. announced on the 29th that it will start clinical trials (clinical trials) of a new type of coronavirus vaccine that is injected into the nose in 2022. Since it is not necessary to inject into patients, it is expected to spread in areas where the medical environment is not sufficiently prepared, such as emerging countries. The timing of commercialization has not been clarified.

　The company develops both vaccines and therapeutics for the new corona. Injectable vaccines will move to final-stage clinical trials later this year. Aim for practical use in FY2009. In addition to the development candidate, the type that sprays into the nose is poised to compete with the preceding Pfizer.

　On the other hand, the therapeutic drug is a drug for mildly ill patients, and the final stage clinical trial was started on the 27th.